Crossmark

Assessment of the safety and gut microbiota modulation ability of an infant formula containing Bifidobacterium animalis ssp. lactis CP-9 or Lactobacillus salivarius AP-32 and the effects of the formula on infant growth outcomes: insights from a four-month clinical study in infants under two months old

Crossref DOI link: https://doi.org/10.1186/s12887-024-05289-7

Published Online: 2024-12-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Shang-Po

Lin, Hung-Chih

Chen, Jui-Fen

Wang, Hui-Shan

Huang, Yen-Yu

Hsia, Ko-Chiang

Lin, Jia-Hung

Kuo, Yi-Wei

Li, Ching-Min

Hsu, Yu-Chieh

Tsai, Shin-Yu

Ho, Hsieh-Hsun
License Information

Text and Data Mining valid from 2024-12-27

Version of Record valid from 2024-12-27
More Information

Article History

Received: 7 December 2023

Accepted: 26 November 2024

First Online: 27 December 2024

Declarations

:

: This study adhered to the guidelines of the Declaration of Helsinki, was approved by the China Medical University & Hospital Research Ethics Committee (IRB No. CMUH108-REC2-005), and was registered with the US Library of Medicine () with the identifier NCT03993301. Written informed consent was obtained from the parents or legal guardians of all participants.

: Not applicable.

: Glac Biotech Co., Ltd. provided financial support in the form of salaries for J. F. Chen, H.S. Wang, Y.Y. Huang, K.C. Hsia, J.H. Lin, Y.W. Kuo, C.M. Li, Y.C. Hsu, S.Y. Tsai, and H.H. Ho but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. S.P. Shen and H.C. Lin declare that they have no competing interests.

Document is current

Any future updates will be listed below